Your session is about to expire
← Back to Search
CTX120 for Multiple Myeloma
This trial is testing a new drug for safety and effectiveness in patients who have multiple myeloma that has returned after treatment or is resistant to treatment.
- Multiple Myeloma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You are 18 years old or older.You have had a stem cell transplant from a donor.You had a stem cell transplant less than 60 days ago and are still dealing with serious problems from it.You have received gene therapy, modified cell therapy, or certain types of cancer treatment before.You have a disorder that weakens your immune system or an autoimmune disease that needs strong medication to control.You are in good enough physical condition to perform daily activities without much difficulty.You have a current infection with HIV, hepatitis B, or hepatitis C.You are in good enough physical shape to perform daily activities without assistance.Your kidneys, liver, heart, and lungs are working well.There is evidence that the multiple myeloma has spread to the central nervous system.You have had another type of cancer, except for certain skin or cervix cancers, that was removed completely and has not come back for at least 5 years.You have multiple myeloma that has come back after treatment and have already tried at least two different treatments.You have or had significant brain or nervous system problems, like seizures, stroke, or autoimmune diseases affecting the brain.You have multiple myeloma that has come back after treatment, and you have already tried at least two different treatments.
- Group 1: CTX120
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this trial have any open slots for enrollees at the moment?
"The clinicaltrials.gov listing for this medical trial reveals that it is not presently looking to include new candidates, despite having been initially posted on 1/22/2020 and lastly updated on 7/14/2022. Nonetheless, 807 other trials are currently accepting patients at this time."
How many North American locations are currently conducting this clinical trial?
"As of now, this medical study is accepting patients at 5 select sites. These include the cities of Philadelphia, Chicago and Nashville as well as two other locations. To reduce travel needs, it would be beneficial to register with a clinic located in close proximity."
Has CTX120 been granted official acceptance by the FDA?
"Our research team has concluded that CTX120 is likely safe, awarding it a score of 1. This assessment was made due to the Phase 1 trial status and limited evidence for efficacy or safety."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends